Independent biopharmaceutical company Specialised Therapeutics announced an expansion of its partnership with Incyte Biosciences International, an affiliate of Incyte Corporation (INCY), to register, commercialize, and distribute ruxolitinib cream (marketed as Opzelura in the U.S. and EU) across Australia.
Ruxolitinib 1.5% cream is
